Vitiligo causes patches of skin to lose pigment, affecting about 1% of people worldwide. Current treatments include topical steroids, light therapy, and the JAK inhibitor ruxolitinib cream (FDA-approved in 2022). Many people see some repigmentation with treatment, though results vary widely across the body.
What's actually going on in research
Trials are testing oral JAK inhibitors that may work faster and reach more areas than creams, newer topical formulations, combination approaches pairing drugs with light therapy, and treatments targeting the autoimmune process that destroys pigment cells. Researchers are also studying melanocyte transplant techniques and drugs that might protect remaining pigment cells.
Oral JAK inhibitors
Pills like ritlecitinib and povorcitinib aim to repigment skin across the body, not just where cream is applied. Early results show meaningful color return in people with active, spreading vitiligo.
Combination therapy
Studies are pairing JAK inhibitors with narrowband UV light, which together may stimulate pigment cells more effectively than either alone. Some trials combine multiple drugs to both stop immune attack and promote repigmentation.
Cell-based treatments
Techniques to transplant melanocytes from normally pigmented skin to white patches are being refined. Some approaches use cultured cells, while others transfer tissue directly during outpatient procedures.
What to know before you search
Eligibility often depends on how much skin is affected, whether vitiligo is spreading, skin type, and whether you've tried topical treatments or light therapy before.
What types of trials are currently open
- Treatment trials — Testing new topical creams, oral medications (especially JAK inhibitors), or injections to restore skin color.
- Combination trials — Pairing drugs with light therapy or testing multiple medications together to see if they work better in tandem.
- Procedural trials — Studying melanocyte transplant techniques, including cultured cell suspensions and tissue grafting methods.
- Prevention trials — Testing whether treatment can prevent vitiligo from spreading in people with recent or limited patches.
- Quality of life studies — Following people with vitiligo to understand treatment impact on daily life, mental health, and camouflage product use.
Recently added Vitiligo trials
An Observational Study of Patients With Dermatologic Disease
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.
Efficacy of Topical Tyrosine Versus Topical 5-Fluorouracil With Fractional Erbium YAG Laser
Vitiligo is an autoimmune disorder affecting the skin, specifically targeting pigment-producing melanocytes, leading to noticeable regions of depigmentation characterized by white spots. It is a widely prevalent skin disorder globally, affecting males and females almost equally, although it is reported slightly more frequently in females. In more than 60% of patients, the disease begins before the age of 30 and It has an estimated prevalence of roughly 0.2-2% across various populations, with around 0.4% in the European-derived white (EUR) population.
Find Vitiligo trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.